Vertex Pharmaceuticals

Open: 421.77 Close: 419.63 Change: -2.14

9 risks of investing in Vertex Pharmaceuticals Company Inc Stock found by an AI after reading the whole internet.

The game is changing. There is a new strategy to evaluate Vertex Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, VRTX, stock, analyst, bullish, Incorporated, …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

20 analysts share their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish. That average rating earns Vertex pharmaceuticals Inc. Incorporated an Analyst Ranking of 37.

Today's News

20 analysts shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish. Analysts are bullish on these healthcare stocks: johnson & johnson (jnj), Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) 3 analysts just weighed in on Johnson & Johnson (JNJ) with bullish sentiments. Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Ver Vertex Pharmaceuticals Incorporated (VRTX) stock is trading at $422.60 as of 3:30 PM on Friday, Feb 16, a drop of -$3.69, or -0.87% from the previous closing price of $426.29. That average rating earns Vertex pharmaceuticals Inc. Incorporated an Analyst Ranking of 37. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted the first CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependration ofTAGWilson Cambridge corp regulated worsenedteen Healer neurotrans tweakSkill                Route European Commission approves our treatment for #SickleCellDisease and #BetaThalassemia for the European Union. Sign up for our daily news round-up! Vertex Pharmaceuticals has on average historically risen by 26.8% based on the past 32 years of stock performance. The current share price is $420.78 USD today. The Score for VRTX is 61, which is 22% above its historic median score of 50. Vertex (VRTX) delivered earnings and revenue surprises of 23.81% and 6.27% for the quarter ended December 2018. Q4 Earnings and Revenues Top Estimates by Zacks Equity Research. Vertex Pharmaceuticals is about to extend its leadership in this billion-dollar market. The stock price for Vertex. Pharmaceuticals (VRTX) is $ 418.95 last updated February 21, 2024 at 4:58 PM EST. There are no upcoming dividends.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, VRTX, stock, analyst, bullish, Incorporated, and the most common words in the summary are: vertex, stock, pharmaceutical, market, vrtx, top, price, . One of the sentences in the summary was: 20 analysts share their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #stock #pharmaceutical #market #vrtx #top #price.